Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danggui Buxue Tang is a traditional Chinese medicine (TCM) herbal decoction first described in 1247 AD by Li Dongyuan. It consists of two herbs—Astragali Radix (roots of Astragalus membranaceus) and Angelicae Sinensis Radix (roots of Angelica sinensis)—in a weight ratio of 5:1. The formula is used to enrich "Blood" and nourish "Qi" according to TCM theory, with modern research supporting its use for stimulating hematopoietic function, exhibiting estrogenic properties, accelerating bone regeneration, promoting immune system activity, protecting cardiovascular health, and enhancing angiogenesis. Major active ingredients include astragaloside IV, calycosin, formononetin (from Astragali Radix), Z-ligustilide and ferulic acid (from Angelicae Sinensis Radix). It is commonly prescribed for women suffering from menopausal symptoms but has broader applications in age-related diseases[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danggui Buxue Tang.